title: Adult height after growth hormone treatment in Japanese children with idiopathic growth hormone deficiency: analysis from the KIGS Japan database.
abstract: OBJECTIVE
  To identify factors affecting adult height in Japanese patients with idiopathic growth hormone deficiency (GHD), who received growth hormone (GH) treatment during childhood.
  
  
  METHODS
  A retrospective pharmaco-epidemiological study of the effect of GH treatment on adult height standard deviation scores (SDS) was conducted in 374 Japanese patients with idiopathic GHD. During childhood, GH (0.146 +/- 0.023 mg/kg/week) was administered for a mean of 6.4 +/- 2.6 years.
  
  
  RESULTS
  The mean adult height was 160.6 +/- 6.3 cm (-1.75 SD; n = 232) in boys and 146.9 +/- 7.3 cm (-2.20 SD; n = 158) in girls after GH therapy. The mean increases in height SDS in boys and girls with severe GHD were 2.13 SD and 1.66 SD, respectively (p < 0.05). These increases were greater than those observed in patients with moderate GHD and mild GHD. The mean adult height of male patients with GHD and gonadotropin deficiency (166.8 cm) was significantly higher (p < 0.05) than that of isolated GHD patients who were either receiving (159.1 cm) or not receiving (160.5 cm) gonadal suppression therapy. The mean adult heights of female patients were 149.6, 146.7, and 146.9 cm, respectively, and these values did not significantly differ.
  
  
  CONCLUSIONS
  Linear multiple regression analyses of Japanese patients with severe GHD (n = 61) revealed three independent variables that influenced adult height: gonadotropin deficiency, initial height SDS and height velocity during the first year after the initiation of GH therapy.
authors.affiliation: Department of Pediatrics, Asahikawa Medical College, Asahikawa, Japan.
authors.forename: Kenji
authors.initials: K
authors.lastname: Fujieda
authors.forename: Toshiaki
authors.initials: T
authors.lastname: Tanaka
authors.forename: Kazue
authors.initials: K
authors.lastname: Takano
authors.forename: Kazuo
authors.initials: K
authors.lastname: Chihara
authors.forename: Yoshiki
authors.initials: Y
authors.lastname: Seino
authors.forename: Minoru
authors.initials: M
authors.lastname: Irie
mesh_terms: D000293:Adolescent; D041923:Adolescent Development / Q000187:drug effects; D000726:Androgen Antagonists / Q000627:therapeutic use; D044466:Asian People; D001827:Body Height / Q000187:drug effects; D002648:Child; D002657:Child Development / Q000187:drug effects; D016208:Databases, Factual; D004965:Estrogen Antagonists / Q000627:therapeutic use; D005260:Female; D006062:Gonadotropins / Q000172:deficiency; D006128:Growth / Q000187:drug effects*; D006130:Growth Disorders / Q000150:complications / Q000188:drug therapy*; D019382:Human Growth Hormone / Q000172:deficiency* / Q000627:therapeutic use*; D006801:Humans; D008297:Male; D011994:Recombinant Proteins / Q000627:therapeutic use*; D012189:Retrospective Studies; D012720:Severity of Illness Index; D013997:Time Factors
chemical_list: D000726:Androgen Antagonists; D004965:Estrogen Antagonists; D006062:Gonadotropins; D011994:Recombinant Proteins; D019382:Human Growth Hormone